News

Oyetewa Asemba, MD, discussed common mistakes in hair loss and pigmentary disorder care, from scalp exams to treatment vehicle selection.

Aaron Farberg, MD, outlines common triggers of generalized pustular psoriasis flares and the role of IL-36 targeted therapy.

At a Dermatology Times Case-Based Roundtable in Las Vegas, clinicians compared topical corticosteroids, newer nonsteroidal agents, and systemic therapy across adult and adolescent AD cases.

Aaron Farberg, MD, reviews the diagnostic challenges of generalized pustular psoriasis and its common mimics across care settings.

Eileen Cheever, PA, discussed family hesitancy toward systemic pediatric psoriasis treatment and age-related treatment gaps in dermatology.

Aaron Farberg, MD, discusses why generalized pustular psoriasis warrants its own awareness day and how it differs immunologically from plaque psoriasis.

Oral JAK1 povorcitinib shows manageable adverse acne and strong responses even after biologic failure, offering an alternative to injections.

Jerry Shapiro, MD, explains VDPHL01's cardiac safety profile and patient-reported outcomes in a phase 2 trial for female pattern hair loss.

This review of the latest dermatological studies includes insights on JAKs in severe HS, reactive cutaneous capillary endothelial proliferation in esophageal SCC, PN treatment preferences, and more.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses TAMES-02 phase 2 trial enrollment and a new blister burden end point in EBS.

Lisa Swanson, MD, FAAD, discussed expanding oral JAK inhibitor options for younger children with atopic dermatitis and alopecia areata.

Envudeucitinib achieved PASI 100 in 54% of continuously treated patients at 48 weeks in the phase 3 ONWARD3 extension study.

Martina Porter, MD, highlights phase 3 data showing povorcitinib boosts hidradenitis suppurativa responses by week 3 and sustains gains to 54 weeks in refractory patients.

See how precision biologics—dupilumab, IL-13/IL-31 blockers, JAK inhibitors, and omalizumab—change treatment for atopic dermatitis and chronic spontaneous urticaria.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Eileen Cheever, PA, discussed how understanding immunologic pathways can strengthen patient counseling and treatment confidence in dermatology.

In this episode, Miles Harrison and Brian Pilcher, PhD, explain investigational ECM injectables that aim to restore tissue scaffold for wound healing and address post–GLP-1 skin quality changes beyond fillers.

Leon Kircik, MD, discusses the allosteric binding mechanism and safety profile data of zasocitinib in hard-to-treat psoriasis presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

FDA clears Labcorp’s NGS tissue test to quickly spot BRAF V600E/K melanoma, guiding targeted BRAF/MEK therapy selection in days.

Sonelokimab met the primary end point in phase 3 IZAR-1, with 42.1% of biologic-naive patients achieving ACR50 at week 16.

HS microbiome studies fuel probiotic hype, but a new review finds evidence too thin for routine use and highlights key research gaps.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Does facial massage with a gua sha improve skin or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Jerry Shapiro, MD, discusses rapid hair growth and safety findings for oral minoxidil, VDPHL01, in female pattern hair loss.

Isoclear regimen combines topical isotretinoin with stage-specific ingredients from active treatment through long-term maintenance

New oral TYK2 inhibitor shows rapid PASI 75/90 skin clearance in phase 2 plaque psoriasis study, with encouraging safety.

The accelerated FDA approval, based on Replimune's phase 2 IGNYTE trial data, gives clinicians a new second-line option for adults with advanced melanoma progressing after anti-PD-1 therapy.

Obesity may blunt biologic psoriasis gains, according to a 4,200‑patient meta‑analysis showing lower PASI responses, but weight alone shouldn’t drive drug choice.

Leon Kircik, MD, outlines phase 3 zasocitinib data on palmoplantar psoriasis skin clearance presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy.

Aaron Farberg, MD, discusses how localized isotretinoin delivery may affect treatment burden, tolerability, and adherence.